The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Respiratory tract infection incl. pneumonia
Publications
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ,
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
The New England journal of medicine 2018 May 03;378;1671-1680 — 2018 May 03 — 1671-1680
Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.
International journal of chronic obstructive pulmonary disease 2017;12;3055-3064 — 2017 — 3055-3064
Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
Annals of the American Thoracic Society 2015 Jan;12;27-34 — 2015 Jan — 27-34
Meta-review: adverse effects of inhaled corticosteroids relevant to older patients.
Drugs 2014 Apr;74;539-47 — 2014 Apr — 539-47
Inhaled corticosteroids in COPD and the risk of serious pneumonia.
Thorax 2013 Nov;68;1029-36 — 2013 Nov — 1029-36